Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.

[1]  R. Motzer,et al.  Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). , 2018 .

[2]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[3]  A. Ravaud,et al.  IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC) , 2018 .

[4]  A. Abernethy,et al.  Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study. , 2017, Gynecologic oncology.

[5]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[6]  T. Choueiri,et al.  Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Motzer,et al.  Systemic Therapy for Metastatic Renal-Cell Carcinoma. , 2017, The New England journal of medicine.

[8]  Frank Bretz,et al.  Estimands: discussion points from the PSI estimands and sensitivity expert group , 2017, Pharmaceutical statistics.

[9]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[10]  Bohdana Ratitch,et al.  Clinical Trials with Missing Data: A Guide for Practitioners , 2014 .

[11]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[12]  A. Abernethy,et al.  Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  R. Motzer,et al.  Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial , 2013, British Journal of Cancer.

[14]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[15]  B. Monk,et al.  Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study. , 2012, Gynecologic oncology.

[16]  D. Cella.  Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. , 2011, The oncologist.

[17]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. V. Von Roenn,et al.  A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). , 2009, Journal of pain and symptom management.

[20]  X. G. Del Muro,et al.  Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  M. Neary,et al.  Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer , 2010, Health and Quality of Life Outcomes.

[22]  W. Bro,et al.  Development and validation of a scale to measure disease-related symptoms of kidney cancer. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[23]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[24]  D. Eton,et al.  Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences , 2005, Evaluation & the health professions.

[25]  D. Fairclough.  Design and analysis of quality of life studies in clinical trials , 2002, Quality of Life Research.

[26]  D. Cella,et al.  Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A Schrag,et al.  The EQ-5D—a generic quality of life measure—is a useful instrument to measure quality of life in patients with Parkinson's disease , 2000, Journal of neurology, neurosurgery, and psychiatry.

[28]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[29]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[31]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.